Biological Intellectual Property Protection Act of 2025
- Sponsor
- Rep. Davidson, Warren [R-OH-8]
- Committees
- Foreign Affairs Committee (primary)
- Last action
- Apr 22, 2026
Bottom line
The bill establishes new export controls on digital synthetic biology sequences to safeguard U.S. intellectual property and national security from foreign adversaries, primarily China.
What it actually does
This bill amends the Export Control Reform Act of 2018 to mandate a license requirement for the export, reexport, or in-country transfer of digital sequences of synthetic DNA or RNA to "foreign entities of concern." It aims to prevent foreign adversaries, particularly the People's Republic of China, from acquiring sensitive U.S. biotechnology intellectual property and data for military, intelligence, or human rights abuse purposes. The bill includes definitions for key terms like "digital sequence" and "synthetic DNA or RNA," and cross-references existing law for "foreign country of concern."
Proponents argue
Proponents argue that this legislation is a critical national security measure, essential for protecting sensitive U.S. biotechnology intellectual property from systematic exploitation by foreign adversaries like China. They emphasize that China's military-civil fusion strategy and national security laws compel its entities to support military modernization, making export controls on dual-use technologies like synthetic biology imperative to maintain U.S. technological leadership and prevent misuse.
Opponents contend
Opponents might contend that such broad export restrictions could impede legitimate international scientific collaboration, slow down global research progress, and create significant regulatory burdens for U.S. biotechnology companies and academic institutions. They may also argue that overly restrictive measures could inadvertently disadvantage U.S. competitiveness by making it harder for U.S. entities to engage in global markets and research partnerships, potentially driving innovation elsewhere.
The bill is concise and clearly structured, allowing for a quick yet thorough review of its provisions and implications.
Section 1
Short Title
This section formally names the bill the "Biological Intellectual Property Protection Act of 2025." This provides a concise and official reference for the legislation, making it easier to identify and discuss within legislative and public discourse.
Supporters argue
Supporters argue that a clear and descriptive short title helps communicate the bill's purpose and intent to the public and other legislators, facilitating understanding and engagement.
Critics contend
No specific opposition is typically raised against the naming of a bill, as it is a standard legislative practice.
Tradeoffs
None.
Section 2
Congressional Findings on Threats from Foreign Adversaries
This section articulates Congress's belief that the People's Republic of China systematically exploits U.S. intellectual property and sensitive data for military modernization, intelligence activities, and human rights abuses. It highlights China's military-civil fusion strategy and its laws compelling citizens to cooperate with national security efforts. The section concludes that exporting novel synthetic DNA and RNA sequences poses a high risk of intellectual property theft by foreign adversaries, necessitating U.S. export controls.
Section 3, inserting new Section 1758A into the Export Control Reform Act of 2018
License Requirement for Export of Digital Synthetic DNA/RNA Sequences
This core provision mandates that, within one year of the bill's enactment, the Secretary (presumably of Commerce) must require a license for the export, reexport, or in-country transfer of digital sequences of synthetic DNA or RNA to "foreign entities of concern." This aims to prevent unauthorized access to sensitive biotechnology designs and intellectual property by designated adversaries, thereby safeguarding U.S. technological advantage in synthetic biology.
Section 3, new Section 1758A(b)
Exception for Publicly Available Information
This subsection specifies that the new license requirement will not apply to information described in section 734.3(b) of the Export Administration Regulations. This existing regulation generally exempts publicly available information, such as that found in open scientific literature, patents, or fundamental research, from export controls. This carve-out aims to prevent the bill from inadvertently restricting the free flow of non-sensitive scientific knowledge.
Section 3, new Section 1758A(c)
Definitions for Export Control Terms
This subsection defines key terms for the new export control section. It clarifies "digital sequence" as a binary or digital representation of DNA/RNA identity and order. "Foreign country of concern" is defined by reference to 42 U.S.C. 19221(a), which includes China, Russia, Iran, and North Korea. "Foreign entity of concern" encompasses government entities, persons subject to the jurisdiction of, or owned/controlled by, a foreign country of concern. "Synthetic DNA or RNA" includes recombinant, chemically synthesized, and replicated nucleic acid molecules.
The bill defines "foreign country of concern" by referencing section 10612(a) of the Research and Development, Competition, and Innovation Act (42 U.S.C. 19221(a)). This existing law explicitly designates the People's Republic of China, the Russian Federation, the Democratic People's Republic of Korea, and the Islamic Republic of Iran as foreign countries of concern.
Section 3, new Section 1758A(c)(2)
Why it matters:This is standard legislative practice to avoid redundancy and ensure consistency with existing legal frameworks and established national security designations.
Case for: Proponents argue that using an existing, established definition ensures clarity and consistency across U.S. law regarding which nations are considered adversaries for technology transfer purposes, leveraging prior legislative consensus.
Case against: Critics might argue that relying on external definitions can obscure the full scope of the bill's impact for readers who do not immediately look up the referenced statute, potentially reducing transparency for the average reader.
Estimated impact: This definition directly determines the primary target nations for the export controls, significantly impacting U.S. relations and scientific/commercial exchanges with China, Russia, Iran, and North Korea in the synthetic biology sector.
The definition of "synthetic DNA or RNA" includes not only molecules constructed by joining nucleic acids and chemically synthesized molecules, but also "molecules that result from the replication of molecules described in subparagraph (A) or (B)." This means any progeny or copies of synthetic DNA/RNA are also covered by the export controls.
Section 3, new Section 1758A(c)(4)
Why it matters:This is standard practice for technical definitions to ensure comprehensive coverage and prevent circumvention by adversaries who might seek to replicate controlled materials after initial acquisition.
Case for: Proponents argue this broad definition is necessary to prevent circumvention, as adversaries could otherwise obtain initial synthetic sequences and then replicate them without falling under export controls, undermining the bill's intent.
Case against: Critics might argue that this broadness could create significant compliance challenges, as tracking the replication and subsequent use of synthetic molecules could be difficult and burdensome, potentially extending controls to a vast array of downstream biological products and processes.
Estimated impact: Expands the scope of controlled items beyond initial designs to include biological materials derived from them, potentially increasing the regulatory burden on laboratories, manufacturers, and researchers working with synthetic biology.